Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleBasic Science Investigations

Targeted Systemic Radiotherapy with scVEGF/177Lu Leads to Sustained Disruption of the Tumor Vasculature and Intratumoral Apoptosis

Francis G. Blankenberg, Zoia Levashova, Michael G. Goris, Carl V. Hamby, Marina V. Backer and Joseph M. Backer
Journal of Nuclear Medicine October 2011, 52 (10) 1630-1637; DOI: https://doi.org/10.2967/jnumed.111.091629
Francis G. Blankenberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zoia Levashova
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael G. Goris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carl V. Hamby
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marina V. Backer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph M. Backer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 52 no. 10 1630-1637
DOI 
https://doi.org/10.2967/jnumed.111.091629
PubMed 
21890879

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication April 8, 2011
  • Accepted for publication May 24, 2011
  • Published online October 3, 2011.

Article Versions

  • previous version (September 2, 2011 - 05:20).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2011 by Society of Nuclear Medicine

Author Information

  1. Francis G. Blankenberg1,
  2. Zoia Levashova1,
  3. Michael G. Goris1,
  4. Carl V. Hamby2,
  5. Marina V. Backer3 and
  6. Joseph M. Backer3
  1. 1Department of Radiology/MIPS, Stanford University, Palo Alto, California
  2. 2Department of Microbiology and Immunology, New York Medical College, Valhalla, New York; and
  3. 3Sibtech, Inc., Brookfield, Connecticut
  1. For correspondence contact: Francis G. Blankenberg, Lucile Salter Packard Children's Hospital at Stanford, 725 Welch Rd., Room 1673, Stanford, CA 94304-1601. E-mail: blankenb{at}stanford.edu
View Full Text

Statistics from Altmetric.com

Cited By...

  • 13 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Advances in Anticancer Radiopharmaceuticals
    M.R. Jackson, N. Falzone, K.A. Vallis
    Clinical Oncology 2013 25 10
  • The Role of VEGF Receptors as Molecular Target in Nuclear Medicine for Cancer Diagnosis and Combination Therapy
    Katarzyna Masłowska, Paweł Krzysztof Halik, Dagmara Tymecka, Aleksandra Misicka, Ewa Gniazdowska
    Cancers 2021 13 5
  • Direct measurements of VEGF–VEGFR2 binding affinities reveal the coupling between ligand binding and receptor dimerization
    Christopher King, Kalina Hristova
    Journal of Biological Chemistry 2019 294 23
  • New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts
    Morten Persson, Palle Rasmussen, Jacob Madsen, Michael Ploug, Andreas Kjaer
    Nuclear Medicine and Biology 2012 39 7
  • Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model
    Jessie R. Nedrow, Anders Josefsson, Sunju Park, Tom Bäck, Robert F. Hobbs, Cory Brayton, Frank Bruchertseifer, Alfred Morgenstern, George Sgouros
    EJNMMI Research 2017 7 1
  • Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF–NGR using multi-modal imaging
    Thorsten Persigehl, Janine Ring, Christoph Bremer, Walter Heindel, Richard Holtmeier, Jörg Stypmann, Michael Claesener, Sven Hermann, Michael Schäfers, Caroline Zerbst, Christoph Schliemann, Rolf M. Mesters, Wolfgang E. Berdel, Christian Schwöppe
    Angiogenesis 2014 17 1
  • Imaging VEGF receptor expression to identify accelerated atherosclerosis
    Yared Tekabe, Maria Kollaros, Adam Zerihoun, Geping Zhang, Marina V Backer, Joseph M Backer, Lynne L Johnson
    EJNMMI Research 2014 4 1
  • Combined Ibuprofen-Nanoconjugate Micelles with E-Selectin for Effective Sunitinib Anticancer Therapy
    Xianhu Zeng, Yi Teng, Chunrong Zhu, Zhipeng Li, Tian Liu, Yong Sun, Shangcong Han
    International Journal of Nanomedicine 2022 Volume 17
  • Evaluation of 177Lu-CHX-A′′-DTPA-Bevacizumab as a radioimmunotherapy agent targeting VEGF expressing cancers
    Mythili Kameswaran, Usha Pandey, Naresh Gamre, K.V. Vimalnath, Haladhar Dev Sarma, Ashutosh Dash
    Applied Radiation and Isotopes 2016 114
  • Targeted scVEGF/177Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy
    Mary Rusckowski, Yuzhen Wang, Francis G. Blankenberg, Zoia Levashova, Marina V. Backer, Joseph M. Backer
    EJNMMI Research 2016 6 1

Article usage

Article usage: September 2011 to April 2025

AbstractFullPdf
Sep 2011349137
Oct 20117071756
Nov 20112671124
Dec 20111362221
Jan 201273814
Feb 20126799
Mar 20125968
Apr 2012581014
May 2012662323
Jun 2012311113
Jul 2012381323
Aug 2012231216
Sep 2012341415
Oct 2012321412
Nov 2012452015
Dec 2012372416
Jan 2013312812
Feb 2013576513
Mar 20132686
Apr 2013232011
May 2013442811
Jun 201313127
Jul 20132177
Aug 201331515
Sep 20131522
Oct 201317510
Nov 2013171628
Dec 20132056110
Jan 2014122343
Feb 2014113261
Mar 2014211934
Apr 2014123666
May 2014145090
Jun 2014104896
Jul 2014241731
Aug 201452748
Sep 20141154100
Oct 2014201730
Nov 2014152140
Dec 201471216
Jan 201514410
Feb 20151877
Mar 201525113
Apr 20151158
May 201516125
Jun 2015873
Jul 2015779
Aug 201512147
Sep 20151673
Oct 20151064
Nov 2015787
Dec 201521166
Jan 2016231315
Feb 20166317
Mar 201611622
Apr 20167510
May 20169410
Jun 201612115
Jul 201618811
Aug 20162077
Sep 201618159
Oct 2016241213
Nov 2016151111
Dec 201616107
Jan 201715106
Feb 201718174
Mar 201723123
Apr 20172771
May 201718196
Jun 20178105
Jul 20179123
Aug 201715147
Sep 2017141810
Oct 201717155
Nov 201723184
Dec 201722235
Jan 20188117
Feb 201820163
Mar 2018112110
Apr 201814193
May 201810271
Jun 201825253
Jul 201817182
Aug 20188172
Sep 201811212
Oct 201811345
Nov 20189280
Dec 20186462
Jan 201915383
Feb 201926451
Mar 201923517
Apr 201923272
May 201910118
Jun 201910915
Jul 2019211818
Aug 201916158
Sep 20191054
Oct 2019883
Nov 20191236
Dec 2019923
Jan 20201277
Feb 20201038
Mar 2020836
Apr 2020877
May 20203206
Jun 20207311
Jul 20201003
Aug 2020222
Sep 2020836
Oct 20201047
Nov 20201144
Dec 202041616
Jan 20213811
Feb 20214128
Mar 20211124
Apr 20212810
May 2021296
Jun 2021296
Jul 20211107
Aug 20211108
Sep 20211199
Oct 202131023
Nov 20214914
Dec 20211133
Jan 202231813
Feb 2022343
Mar 20222148
Apr 202211010
May 20220911
Jun 2022148
Jul 20220148
Aug 2022096
Sep 20220812
Oct 2022183
Nov 2022197
Dec 20224157
Jan 20231168
Feb 2023361
Mar 20233195
Apr 20230186
May 20235103
Jun 2023071
Jul 2023072
Aug 2023269
Sep 2023182
Oct 2023295
Nov 2023488
Dec 20236295
Jan 20243124
Feb 20243103
Mar 2024052
Apr 202471511
May 20242196
Jun 20248810
Jul 20243109
Aug 202441812
Sep 20242109
Oct 202461715
Nov 20243412
Dec 20245149
Jan 202531614
Feb 20252619
Mar 202552210
Apr 202522929
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 52 (10)
Journal of Nuclear Medicine
Vol. 52, Issue 10
October 1, 2011
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Targeted Systemic Radiotherapy with scVEGF/177Lu Leads to Sustained Disruption of the Tumor Vasculature and Intratumoral Apoptosis
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Targeted Systemic Radiotherapy with scVEGF/177Lu Leads to Sustained Disruption of the Tumor Vasculature and Intratumoral Apoptosis
Francis G. Blankenberg, Zoia Levashova, Michael G. Goris, Carl V. Hamby, Marina V. Backer, Joseph M. Backer
Journal of Nuclear Medicine Oct 2011, 52 (10) 1630-1637; DOI: 10.2967/jnumed.111.091629

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Targeted Systemic Radiotherapy with scVEGF/177Lu Leads to Sustained Disruption of the Tumor Vasculature and Intratumoral Apoptosis
Francis G. Blankenberg, Zoia Levashova, Michael G. Goris, Carl V. Hamby, Marina V. Backer, Joseph M. Backer
Journal of Nuclear Medicine Oct 2011, 52 (10) 1630-1637; DOI: 10.2967/jnumed.111.091629
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE STATEMENT
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Direct measurements of VEGF-VEGFR2 binding affinities reveal the coupling between ligand binding and receptor dimerization
  • Google Scholar

More in this TOC Section

  • Tumor Uptake of Anti-CD20 Fabs Depends on Tumor Perfusion
  • How Sensitive Is the Upper Gastrointestinal Tract to 90Y Radioembolization? A Histologic and Dosimetric Analysis in a Porcine Model
  • 11C-Methionine PET of Myocardial Inflammation in a Rat Model of Experimental Autoimmune Myocarditis
Show more Basic Science Investigations

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire